JBT Marel
JBTM
104.33
-4.36
-4.01%
JBT Marel
US · JBTM
#1997 by market cap
Listed 1970
104.33
-4.36
-4.01%
Live - 5344 symbols - heartbeat 287s ago
· 2026-10-08 07:39
Pre-market
103.70
-0.60%
After-hours
104.40
+0.07%
- Market cap
- 5.41B
- P/E (TTM)i
- 28.27
- P/Bi
- 1.21
- EPSi
- -0.98
- Div yieldi
- 0.38%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on JBTM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.67, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +121.34% YoY
Margins
- Gross margin
- 35.14%
- Operating margin
- 5.76%
- Net margin
- -1.33%
Key ratios & quality
- Enterprise valuei
- 7.13B
- Altman Z-Scorei
- 1.67
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.92B | 1.95B | 1.73B | 1.40B | 1.59B | 1.66B | 1.72B | 3.80B |
| Gross profit | 537.60M | 598.10M | 533.70M | 482.10M | 529.40M | 585.70M | 626.50M | 1.33B |
| Selling & admin expenses | 346.80M | 396.40M | 358.50M | 351.40M | 389.70M | 409.60M | 506.70M | 1.12B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 190.80M | 201.70M | 175.20M | 130.70M | 139.70M | 176.10M | 119.80M | 218.70M |
| Pretax profit | 129.00M | 166.90M | 145.50M | 119.50M | 120.00M | 153.10M | 95.40M | -62.40M |
| Tax | 24.60M | 37.60M | 36.70M | 27.00M | 16.20M | 23.50M | 10.70M | -13.10M |
| Net profit | 104.70M | 129.60M | 108.80M | 119.10M | 137.40M | 582.60M | 85.40M | -50.50M |
| Basic EPS | 3 | 4 | 3 | 4 | 4 | 18 | 3 | -1 |
| Diluted EPS | 3.23 | 4.02 | 3.39 | 3.71 | 4.28 | 18.13 | 2.65 | -0.98 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 854.00M | 935.00M | 1.00B | 1.01B | 936.00M | 981.00M |
| Gross profit | 292.00M | 335.00M | 359.80M | 348.10M | 329.00M | 359.00M |
| Selling & admin expenses | 325.00M | 287.00M | 222.00M | 361.80M | 261.00M | 313.00M |
| Research & development | -- | -- | 28.70M | -- | -- | -- |
| Operating profit | -33.00M | 48.00M | 109.10M | 79.50M | 68.00M | 46.00M |
| Pretax profit | -219.00M | 11.00M | 83.70M | 61.50M | 60.00M | 35.00M |
| Tax | -46.00M | 8.00M | 17.10M | 8.10M | 15.00M | 7.00M |
| Net profit | -173.00M | 3.00M | 66.00M | 53.10M | 45.00M | 28.00M |
| Basic EPS | -3 | 0 | 1 | 1 | 1 | 1 |
| Diluted EPS | -3.35 | 0.07 | 1.26 | 1.01 | 0.86 | 0.54 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 618.50M | 708.20M | 616.10M | 718.70M | 926.50M | 1.10B | 1.86B | 1.58B |
| Cash & ST investments | 43.00M | 39.50M | 47.50M | 78.80M | 71.70M | 483.30M | 1.23B | 167.90M |
| Inventory | 206.10M | 245.00M | 197.30M | 229.10M | 264.00M | 238.90M | 233.10M | 643.70M |
| Total assets | 1.44B | 1.91B | 1.81B | 2.14B | 2.64B | 2.71B | 3.41B | 8.19B |
| Total current liabilities | 485.30M | 474.50M | 457.50M | 549.90M | 624.00M | 484.40M | 535.50M | 1.62B |
| Short-term debt | 500.00K | 900.00K | 2.40M | -- | 600.00K | -- | -- | 411.90M |
| Long-term debt | 387.10M | 698.30M | 522.50M | 674.40M | 977.30M | 646.40M | 1.25B | 1.47B |
| Total liabilities | 985,600,000.00 | 1,345,400,000.00 | 1,168,800,000.00 | 1,390,900,000.00 | 1,735,600,000.00 | 1,221,500,000.00 | 1,869,600,000.00 | 3,726,900,000.00 |
| Total equity | 456.90M | 569.50M | 637.10M | 750.50M | 905.40M | 1.49B | 1.54B | 4.46B |
| Retained earnings | 416.50M | 532.80M | 627.80M | 733.40M | 894.00M | 1.46B | 1.54B | 1.46B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.49B | 1.53B | 1.54B | 1.58B | 1.68B | 1.61B |
| Cash & ST investments | 101.00M | 111.80M | 114.90M | 167.90M | 211.00M | 93.00M |
| Inventory | 613.50M | 661.10M | 669.40M | 643.70M | 667.00M | 700.00M |
| Total assets | 8.00B | 8.25B | 8.20B | 8.19B | 8.16B | 8.01B |
| Total current liabilities | 1.18B | 1.64B | 1.65B | 1.62B | 1.66B | 1.30B |
| Short-term debt | 21.40M | 410.20M | 411.40M | 411.90M | 411.00M | 9.00M |
| Long-term debt | 1.97B | 1.51B | 1.50B | 1.47B | 1.43B | 1.67B |
| Total liabilities | 3,892,000,000.00 | 3,877,700,000.00 | 3,778,600,000.00 | 3,726,900,000.00 | 3,680,000,000.00 | 3,534,000,000.00 |
| Total equity | 4.11B | 4.37B | 4.42B | 4.46B | 4.48B | 4.47B |
| Retained earnings | 1.36B | 1.36B | 1.42B | 1.46B | 1.51B | 1.53B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 153.90M | 110.20M | 252.00M | 174.90M | 135.20M | 74.20M | 232.60M | 341.70M |
| Depreciation & amortization | 57.70M | 65.60M | 71.80M | 72.10M | 76.20M | 91.30M | 89.40M | 266.20M |
| Free cash flow | 114.10M | 72.30M | 217.70M | 123.20M | 50.60M | 19.10M | 194.70M | 238.10M |
| Dividends paid | -13.10M | -12.70M | -12.80M | -12.80M | -13.10M | -12.80M | -13.10M | -20.90M |
| Stock buybacks / issuance | -20.00M | -- | -- | 0 | -7.70M | -5.10M | 0 | 0 |
| Ending cash balance | 43.00M | 39.50M | 47.50M | 76.90M | 71.70M | 483.30M | 1.23B | 186.50M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 34.00M | 103.00M | 87.30M | 117.40M | 119.00M | 102.00M |
| Depreciation & amortization | 61.00M | 82.00M | 55.50M | 67.70M | 68.00M | 66.00M |
| Free cash flow | 14.00M | 84.00M | 56.60M | 83.50M | 93.00M | 77.00M |
| Dividends paid | -5.00M | -6.00M | -4.70M | -5.20M | -5.00M | -6.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 119.00M | 130.00M | 133.30M | 186.50M | 230.00M | 112.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 23.16 | 25.14 | 18.03 | 17.07 | 16.21 | 49.56 | 5.63 | -1.68 |
| ROA %i | 7.35 | 7.68 | 5.85 | 6.00 | 5.53 | 22.01 | 2.79 | -0.87 |
| ROIC %i | 13.82 | 13.59 | 9.81 | 9.68 | 8.74 | 29.78 | 3.31 | 0.65 |
| 5-year avg ROE %i | 32.03 | 32.56 | 27.18 | 21.88 | 20.02 | 25.12 | 21.22 | 17.28 |
| EBIT margin %i | 7.44 | 9.54 | 9.23 | 8.64 | 7.77 | 10.66 | 6.69 | 1.37 |
| FCF / sales %i | 5.94 | 3.72 | 12.60 | 9.18 | 2.53 | 1.15 | 11.35 | 6.27 |
| Current ratioi | 1.27 | 1.49 | 1.35 | 1.31 | 1.48 | 2.27 | 3.48 | 0.98 |
| Quick ratioi | 0.76 | 0.85 | 0.77 | 0.75 | 0.54 | 1.59 | 2.92 | 0.45 |
| Debt / assetsi | 26.87 | 36.51 | 29.07 | 31.49 | 37.03 | 23.85 | 36.68 | 22.98 |
| LT debt / equityi | 84.72 | 122.62 | 82.01 | 89.90 | 107.94 | 43.41 | 81.08 | 32.93 |
| Interest coveragei | 10.28 | 9.88 | 11.47 | 18.55 | 11.86 | 7.30 | 5.92 | 0.45 |
| Revenue CAGR (3Y) %i | 20.13 | 12.94 | 1.86 | -9.97 | -6.50 | -1.24 | 7.00 | 33.67 |
| Net income CAGR (3Y) %i | 23.03 | 24.04 | 10.56 | 4.59 | 2.13 | 74.95 | -10.49 | -- |
| FCF CAGR (3Y) %i | 15.42 | 33.63 | 48.34 | 2.59 | -11.22 | -55.57 | 16.48 | 67.57 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.94 | -4.67 | -3.68 | -1.68 | 3.90 | 4.35 |
| ROA %i | -2.07 | -2.52 | -2.01 | -0.87 | 2.07 | 2.37 |
| ROIC %i | -1.99 | -1.82 | -0.77 | 0.65 | 3.74 | 3.09 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.40 | -3.10 | -0.83 | 1.37 | 7.73 | 3.85 |
| FCF / sales %i | 9.61 | 10.40 | 8.39 | 6.27 | 8.17 | 7.90 |
| Current ratioi | 1.26 | 0.93 | 0.93 | 0.98 | 1.01 | 1.24 |
| Quick ratioi | 0.54 | 0.40 | 0.40 | 0.45 | 0.48 | 0.52 |
| Debt / assetsi | 24.85 | 23.28 | 23.25 | 22.98 | 22.58 | 20.97 |
| LT debt / equityi | 47.87 | 34.54 | 33.82 | 32.93 | 31.94 | 37.34 |
| Interest coveragei | -1.63 | -0.97 | -0.25 | 0.45 | 3.60 | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Prepared Food and Beverage Solutions is the largest reported line at 52.40% of revenue, across 2 reported segments.
- Protein Solutions follows at 47.60%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Prepared Food and Beverage Solutions52.40%
Protein Solutions47.60%
Quote time 2026-10-08 07:39:51 · For reference only, not investment advice and not tailored to your situation.